Ravindra Majeti MD, PhD

Professional Education

Residency: Brigham and Women's Hospital Harvard Medical School (2004) MA

Board Certification: Hematology, American Board of Internal Medicine (2007)

Fellowship: Stanford University Medical Center (2008) CA

Board Certification: Internal Medicine, American Board of Internal Medicine (2005)

Medical Education: University of California San Francisco (2002) CA

Honors & Awards

Career Award for Medical Scientists, Burroughs Wellcome Fund (2008)

Administrative Appointments

MSTP Admissions Committee, Stanford School of Medicine, 2010

Preleukemic mutations in human acute myeloid leukemia affect epigenetic regulators and persist in remission.
Corces-Zimmerman, M. R., Hong, W.-J., Weissman, I. L., Medeiros, B. C., & Majeti, R. (2014). Preleukemic mutations in human acute myeloid leukemia affect epigenetic regulators and persist in remission. Proceedings of the National Academy of Sciences of the United States of America, 111(7), 2548-2553.

Clonal Evolution of Preleukemic Hematopoietic Stem Cells Precedes Human Acute Myeloid Leukemia
Jan, M., Snyder, T. M., Corces-Zimmerman, M. R., Vyas, P., Weissman, I. L., & Majeti, R. (2012). Clonal Evolution of Preleukemic Hematopoietic Stem Cells Precedes Human Acute Myeloid Leukemia. SCIENCE TRANSLATIONAL MEDICINE, 4(149).

Prospective separation of normal and leukemic stem cells based on differential expression of TIM3, a human acute myeloid leukemia stem cell marker
Jan, M., Chao, M. P., Cha, A. C., Alizadeh, A. A., Gentles, A. J., & Majeti, R. (2011). Prospective separation of normal and leukemic stem cells based on differential expression of TIM3, a human acute myeloid leukemia stem cell marker. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 108(12), 5009-5014.

Association of a Leukemic Stem Cell Gene Expression Signature With Clinical Outcomes in Acute Myeloid Leukemia
Gentles, A. J., Plevritis, S. K., Majeti, R., & Alizadeh, A. A. (2010). Association of a Leukemic Stem Cell Gene Expression Signature With Clinical Outcomes in Acute Myeloid Leukemia. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 304(24), 2706-2715.

Anti-CD47 Antibody Synergizes with Rituximab to Promote Phagocytosis and Eradicate Non-Hodgkin Lymphoma
Chao, M. P., Alizadeh, A. A., Tang, C., Myklebust, J. H., Varghese, B., & Majeti, R. (2010). Anti-CD47 Antibody Synergizes with Rituximab to Promote Phagocytosis and Eradicate Non-Hodgkin Lymphoma. CELL, 142(5), 699-713.

CD47 Is an Adverse Prognostic Factor and Therapeutic Antibody Target on Human Acute Myeloid Leukemia Stem Cells
Majeti, R., Chao, M. P., Alizadeh, A. A., Pang, W. W., Jaiswal, S., & Weissman, I. L. (2009). CD47 Is an Adverse Prognostic Factor and Therapeutic Antibody Target on Human Acute Myeloid Leukemia Stem Cells. CELL, 138(2), 286-299.

Dysregulated gene expression networks in human acute myelogenous leukemia stem cells
Majetl, R., Becker, M. W., Tian, Q., Lee, T.-L. M., Yan, X., & Weissman, I. L. (2009). Dysregulated gene expression networks in human acute myelogenous leukemia stem cells. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 106(9), 3396-3401.

Identification of a hierarchy of multipotent hematopoietic progenitors in human cord blood
Majeti, R., Park, C. Y., & Weissman, I. L. (2007). Identification of a hierarchy of multipotent hematopoietic progenitors in human cord blood. CELL STEM CELL, 1(6), 635-645.

Centrosome-kinase fusions promote oncogenic signaling and disrupt centrosome function in myeloproliferative neoplasms.
Lee, J. Y., Hong, W.-J., Majeti, R., & Stearns, T. (2014). Centrosome-kinase fusions promote oncogenic signaling and disrupt centrosome function in myeloproliferative neoplasms. PloS one, 9(3).

Transient expression of Bcl6 is sufficient for oncogenic function and induction of mature B-cell lymphoma.
Green, M. R., Vicente-Dueñas, C., Romero-Camarero, I., Long Liu, C., Dai, B., & Sánchez-García, I. (2014). Transient expression of Bcl6 is sufficient for oncogenic function and induction of mature B-cell lymphoma. Nature communications, 5, 3904-?.

Role of DNMT3A, TET2, and IDH1/2 mutations in pre-leukemic stem cells in acute myeloid leukemia
Chan, S. M., & Majeti, R. (2013). Role of DNMT3A, TET2, and IDH1/2 mutations in pre-leukemic stem cells in acute myeloid leukemia. INTERNATIONAL JOURNAL OF HEMATOLOGY, 98(6), 648-657.

Role of cysteine 288 in nucleophosmin cytoplasmic mutations: sensitization to toxicity induced by arsenic trioxide and bortezomib
Huang, M., Thomas, D., Li, M. X., Feng, W., Chan, S. M., & Mitchell, B. S. (2013). Role of cysteine 288 in nucleophosmin cytoplasmic mutations: sensitization to toxicity induced by arsenic trioxide and bortezomib. LEUKEMIA, 27(10), 1970-1980.

Azacitidine fails to eradicate leukemic stem/progenitor cell populations in patients with acute myeloid leukemia and myelodysplasia
Craddock, C., Quek, L., Goardon, N., Freeman, S., Siddique, S., & Vyas, P. (2013). Azacitidine fails to eradicate leukemic stem/progenitor cell populations in patients with acute myeloid leukemia and myelodysplasia. LEUKEMIA, 27(5), 1028-1036.

Clonal evolution of acute leukemia genomes
Jan, M., & Majeti, R. (2013). Clonal evolution of acute leukemia genomes. ONCOGENE, 32(2), 135-140.

The cancer stem cell model: B cell acute lymphoblastic leukaemia breaks the mould
McClellan, J. S., & Majeti, R. (2013). The cancer stem cell model: B cell acute lymphoblastic leukaemia breaks the mould. EMBO MOLECULAR MEDICINE, 5(1), 7-9.

Cyclin-A1 represents a new immunogenic targetable antigen expressed in acute myeloid leukemia stem cells with characteristics of a cancer-testis antigen
Ochsenreither, S., Majeti, R., Schmitt, T., Stirewalt, D., Keilholz, U., & Greenberg, P. D. (2012). Cyclin-A1 represents a new immunogenic targetable antigen expressed in acute myeloid leukemia stem cells with characteristics of a cancer-testis antigen. BLOOD, 119(23), 5492-5501.

The CD47-signal regulatory protein alpha (SIRPa) interaction is a therapeutic target for human solid tumors
Willingham, S. B., Volkmer, J.-P., Gentles, A. J., Sahoo, D., Dalerba, P., & Weissman, I. L. (2012). The CD47-signal regulatory protein alpha (SIRPa) interaction is a therapeutic target for human solid tumors. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 109(17), 6662-6667.

Antibody therapy targeting the CD47 protein is effective in a model of aggressive metastatic leiomyosarcoma
Edris, B., Weiskopf, K., Volkmer, A. K., Volkmer, J.-P., Willingham, S. B., & van de Rijn, M. (2012). Antibody therapy targeting the CD47 protein is effective in a model of aggressive metastatic leiomyosarcoma. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 109(17), 6656-6661.

The CD47-SIRP alpha pathway in cancer immune evasion and potential therapeutic implications
Chao, M. P., Weissman, I. L., & Majeti, R. (2012). The CD47-SIRP alpha pathway in cancer immune evasion and potential therapeutic implications. CURRENT OPINION IN IMMUNOLOGY, 24(2), 225-232.

Treatment advances have not improved the early death rate in acute promyelocytic leukemia
McClellan, J. S., Kohrt, H. E., Coutre, S., Gotlib, J. R., Majeti, R., & Medeiros, B. C. (2012). Treatment advances have not improved the early death rate in acute promyelocytic leukemia. HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 97(1), 133-136.

Programmed cell removal: a new obstacle in the road to developing cancer
Chao, M. P., Majeti, R., & Weissman, I. L. (2012). Programmed cell removal: a new obstacle in the road to developing cancer. NATURE REVIEWS CANCER, 12(1), 58-67.

Extranodal dissemination of non-Hodgkin lymphoma requires CD47 and is inhibited by anti-CD47 antibody therapy
Chao, M. P., Tang, C., Pachynski, R. K., Chin, R., Majeti, R., & Weissman, I. L. (2011). Extranodal dissemination of non-Hodgkin lymphoma requires CD47 and is inhibited by anti-CD47 antibody therapy. BLOOD, 118(18), 4890-4901.

Surprise! HSC Are Aberrant in Chronic Lymphocytic Leukemia
Alizadeh, A. A., & Majeti, R. (2011). Surprise! HSC Are Aberrant in Chronic Lymphocytic Leukemia. CANCER CELL, 20(2), 135-136.

Single-cell phospho-specific flow cytometric analysis demonstrates biochemical and functional heterogeneity in human hematopoietic stem and progenitor compartments
Gibbs, K. D., Gilbert, P. M., Sachs, K., Zhao, F., Blau, H. M., & Majeti, R. (2011). Single-cell phospho-specific flow cytometric analysis demonstrates biochemical and functional heterogeneity in human hematopoietic stem and progenitor compartments. BLOOD, 117(16), 4226-4233.

Monoclonal antibody therapy directed against human acute myeloid leukemia stem cells
Majeti, R. (2011). Monoclonal antibody therapy directed against human acute myeloid leukemia stem cells. ONCOGENE, 30(9), 1009-1019.

Therapeutic Antibody Targeting of CD47 Eliminates Human Acute Lymphoblastic Leukemia
Chao, M. P., Alizadeh, A. A., Tang, C., Jan, M., Weissman-Tsukamoto, R., & Majeti, R. (2011). Therapeutic Antibody Targeting of CD47 Eliminates Human Acute Lymphoblastic Leukemia. CANCER RESEARCH, 71(4), 1374-1384.

Human Acute Myelogenous Leukemia Stem Cells Revisited: There's More Than Meets the Eye
Majeti, R., & Weissman, I. L. (2011). Human Acute Myelogenous Leukemia Stem Cells Revisited: There's More Than Meets the Eye. CANCER CELL, 19(1), 9-10.

Calreticulin Is the Dominant Pro-Phagocytic Signal on Multiple Human Cancers and Is Counterbalanced by CD47
Chao, M. P., Jaiswal, S., Weissman-Tsukamoto, R., Alizadeh, A. A., Gentles, A. J., & Weissman, I. L. (2010). Calreticulin Is the Dominant Pro-Phagocytic Signal on Multiple Human Cancers and Is Counterbalanced by CD47. SCIENCE TRANSLATIONAL MEDICINE, 2(63).

Second-line mitoxantrone, etoposide, and cytarabine for acute myeloid leukemia: A single-center experience
Kohrt, H. E., Patel, S., Ho, M., Owen, T., Pollyea, D. A., & Medeiros, B. C. (2010). Second-line mitoxantrone, etoposide, and cytarabine for acute myeloid leukemia: A single-center experience. AMERICAN JOURNAL OF HEMATOLOGY, 85(11), 877-881.

Metastatic Cancer Stem Cells: An Opportunity for Improving Cancer Treatment?
Diehn, M., & Majeti, R. (2010). Metastatic Cancer Stem Cells: An Opportunity for Improving Cancer Treatment?. CELL STEM CELL, 6(6), 502-503.

Macrophages as mediators of tumor immunosurveillance
Jaiswal, S., Chao, M. P., Majeti, R., & Weissman, I. L. (2010). Macrophages as mediators of tumor immunosurveillance. TRENDS IN IMMUNOLOGY, 31(6), 212-219.

Immunophenotypic features of acute myeloid leukemia with inv(3)(q21q26.2)/t(3;3)(q21;q26.2)
Medeiros, B. C., Kohrt, H. E., Arber, D. A., Bangs, C. D., Cherry, A. M., & Alizadeh, A. A. (2010). Immunophenotypic features of acute myeloid leukemia with inv(3)(q21q26.2)/t(3;3)(q21;q26.2). LEUKEMIA RESEARCH, 34(5), 594-597.

Early Mortality in Acute Promyelocytic Leukemia May Be Higher Than Previously Reported.
Alizadeh, A. A., McClellan, J. S., Gotlib, J. R., Coutre, S., Majeti, R., & Medeiros, B. C. (2009). Early Mortality in Acute Promyelocytic Leukemia May Be Higher Than Previously Reported. BLOOD, 114(22), 420-421.

Is Time of the Essence in Adult Acute Myeloid Leukemia (AML)? Time to Blast Clearance and Time to Induction Therapy Fail to Predict Overall Survival (OS).
Kohrt, H. E., Patel, S., Ho, M., Owen, T., Majeti, R., & Alizadeh, A. A. (2009). Is Time of the Essence in Adult Acute Myeloid Leukemia (AML)? Time to Blast Clearance and Time to Induction Therapy Fail to Predict Overall Survival (OS). BLOOD, 114(22), 646-647.

CD47 Is Upregulated on Circulating Hematopoietic Stem Cells and Leukemia Cells to Avoid Phagocytosis
Jaiswal, S., Jamieson, C. Hm., Pang, W. W., Park, C. Y., Chao, M. P., & Weissman, I. L. (2009). CD47 Is Upregulated on Circulating Hematopoietic Stem Cells and Leukemia Cells to Avoid Phagocytosis. CELL, 138(2), 271-285.

The Adhesion Molecule Esam1 Is a Novel Hematopoietic Stem Cell Marker
Ooi, A. Gl., Karsunky, H., Majeti, R., Butz, S., Vestweber, D., & Forsberg, E. C. (2009). The Adhesion Molecule Esam1 Is a Novel Hematopoietic Stem Cell Marker. STEM CELLS, 27(3), 653-661.

In vivo evaluation of human hematopoiesis through xenotransplantation of purified hematopoietic stem cells from umbilical cord blood
Park, C. Y., Majeti, R., & Weissman, I. L. (2008). In vivo evaluation of human hematopoiesis through xenotransplantation of purified hematopoietic stem cells from umbilical cord blood. NATURE PROTOCOLS, 3(12), 1932-1940.